Gilead Sciences Analyst Ratings
Gilead Upgraded to Outperform by Leerink on PreEP Outlook
Leerink Partners Upgrades Gilead Sciences(GILD.US) to Buy Rating, Announces Target Price $96
Leerink Partners Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $96
Gilead Sciences Analyst Ratings
Solid Investment Potential: Buy Rating for Gilead Sciences Amid Positive Revenue Adjustments and Growth Commitment
Gilead Sciences Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $94
Gilead Sciences Analyst Ratings
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies Sticks to Its Buy Rating for Gilead Sciences (GILD)
Morgan Stanley Adjusts Price Target on Gilead Sciences to $84 From $79
Morgan Stanley Remains a Hold on Gilead Sciences (GILD)
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $100
Gilead Sciences Is Maintained at Overweight by JP Morgan
Gilead Sciences Analyst Ratings
Raymond James Adjusts Gilead Sciences Price Target to $95 From $94
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $100
Analysts Offer Insights on Healthcare Companies: Accolade (ACCD) and Gilead Sciences (GILD)
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95